Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial

Roellig C, Steffen B, Schliemann C, Mikesch JH, Alakel N, Herbst R, Haenel M, Noppeney R, Hanoun M, Kaufmann M, Racil Z, Schaefer-Eckart K, Sauer T, Neubauer A, Baldus CD, Mertova J, Jost E, Niemann D, Novak J, Krause S, Scholl S, Hochhaus A, Held G, Szotkowski T, Schmid C, Rank A, Fransecky L, Kramer M, Fiebig F, Haake A, Stoelzel F, Schetelig J, Middeke JM, Platzbecker U, Thiede C, Mueller-Tidow C, Berdel WE, Serve H, Ehninger G, Mayer J, Bornhaeuser M (2022)


Publication Type: Conference contribution

Publication year: 2022

Journal

Publisher: AMER SOC HEMATOLOGY

City/Town: WASHINGTON

Conference Proceedings Title: BLOOD

Event location: New Orleans, LA US

DOI: 10.1182/blood-2022-157126

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Roellig, C., Steffen, B., Schliemann, C., Mikesch, J.-H., Alakel, N., Herbst, R.,... Bornhaeuser, M. (2022). Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial. In BLOOD. New Orleans, LA, US: WASHINGTON: AMER SOC HEMATOLOGY.

MLA:

Roellig, Christoph, et al. "Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial." Proceedings of the 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), New Orleans, LA WASHINGTON: AMER SOC HEMATOLOGY, 2022.

BibTeX: Download